Resources | Press Releases |Press Release

Regulatory News:

Artimplant (STO:ARTIB) publishes Year-End Report 2009 on February 11 2010 at approximately 8:45 AM (CET). The Interim Report is presented by CEO Hans Rosén and CFO Lars-Johan Cederbrant in conference call on February 11 2010 at 11 AM (CET).

The presentation will be in Swedish.

Date: Thursday, February 11, 2010Time: 11:00 AM Central European Time (CET)

Dial in numbers:Swedish participants: +46 (0)8 506 269 04UK participants: +44 207 108 6205US participants: +1 8666 765 870

A presentation in PDF format will be available at the link below a couple of minutes before the conference call starts.

Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html

About ArtimplantArtimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications.

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the healthcare sector.

Forward-looking statementsThis press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on February 8 2010 at 08:00 AM (CET).

This information was brought to you by Cision http://www.cisionwire.com